Abstract
Exon del 19 and L858R mutations account for 90% of EGFR mutant NSCLC. LUX lung 3/6 initially reported a survival difference between these two. However other studies did not demonstrate the same. By using ML, it is possible to discover novel patterns between data and predict cancer susceptibility, recurrence, prognostication, and therapy. This is a real-world study which aims to evaluate effect of these two molecular subtypes on OS/PFS.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
